Thrombophilic mutations in high-risk atrial fibrillation patients: High prevalence of prothrombin gene G20210A polymorphism and lack of correlation with thromboembolism

Thrombosis and Haemostasis

Volumn 90, Issue 6, 2003, Pages 1158-1162

  Poli, Daniela ^a   Antonucci, Emilia ^a   Cecchi, Emanuele ^a   Betti, Irene ^a   Valdrè, Lelia ^b   Mugnaini, Cristina ^c   Alterini, Bruno ^d   Morettini, Alessandro ^d   Nozzoli, Carlo ^d   Abbate, Rosanna ^a   Gensini, Gian Franco ^a   Prisco, Domenico ^a  

^a Universitaria Careggi   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Atrial fibrillation; Factor V Leiden; Prothrombin gene; Stroke

Indexed keywords

ALANINE; BLOOD CLOTTING FACTOR 5 LEIDEN; GLYCINE; PROTHROMBIN;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EMBOLISM; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEREDITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

EID: 0346125292     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-04-0240     Document Type: Article

References (24)

1. Albers G, Dalen J, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119: 194S-206S.
2. Stroke Prevention in Atrial Fibrillation Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with atrial fibrillation. Ann Intern Med 1998; 128: 639-47.
3. Kumagai K, Fukunami M, Ohmori M, et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16: 377-80.
4. Lip GYH, Lowe GDO, Rumley A, et al. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin therapy. Br Heart J 1995; 73: 527-33.
5. Hart RG, Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in patients with Atrial Fibrillation: A meta-analysis. Ann Intern Med 1999; 157: 1237-40.
6. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
7. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untraslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
8. Kotler MN, Mintz GS, Segal BL, et al. Clinical uses of two dimensional echocardiography. Am J Cardiol 1980; 45: 1061-82.
9. Camerota AJ, Crannley JJ, Hayden WG. Ultrasound imaging for carotid occlusive disease. In: Bernstein EF, ed. Noninvasive Diagnosis St Louis, MO: Mosby 1985: 384-95.
10. Feinberg WM, Pearce LA, Hart RG, et al.. Markers of thrombin and platelet activity in patients with atrial fibrilation. Correlation with stroke among 1531 participants in the Stroke Prevention in Atrial Fibrillation III Study. Stroke 1999; 30:2547-253.
11. Redondo M, Watzke HH, Stucki B, et al. Coagulation factors II, V, VII, and X, prothrombin gene 20210G→A transition, and factor V Leiden in coronary artery disease: High factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 1020-5.
12. Gardemann A, Arsic T, Katz N, et al. The factor II G20210A and factor V G1691A gene transition and coronary heart disease. Thromb Haemost 1999; 81: 208-13.
13. Eikelboom JW, Baker RI, Parson R, et al. No association between the 20210G/A prothrombin gene mutation: Premature coronary artery disease. Thromb Haemost 1998; 80: 878-80.
14. Russo G, Girelli D, Olivieri O, et al.. G20210A prothrombin gene polymorphism and prothrombin activity subjects with or without angiographically documented coronary artery disease. Circulation 2001; 103: 2436-40.
15. Rosendaal FR, Siscovick DS, Schwartz SM, et al.. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
16. De Stefano V, Chiusolo P, Paciaroni K, et al.. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-5.
17. Pengo V, Filippi B, Biasiolo A, et al.. Association of the G20210A mutation in the factor II gene with systemic embolism in non-valvular atrial fibrillation. Am J Cardiol 2002; 90: 545-7.
18. Lane DA, Grant PJ. Role of haemostatic gene polymorphisms in venous and arterial thrombotic diseases. Blood 2000; 95: 1517-32.
19. Wolf PA, Robert RD, Kannel WB. Atrial Fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-88.
20. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
21. Lin HJ, Wolf P, Kelly-Hayes M, et al.. Stroke severity in Atrial Fibrillation The Framingham Study. Stroke 1996; 27: 1760-4.
22. Stroke prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.
23. Lip GYH, Lowe GDO. ABC of atrial fibrillation: Antithrombotic treatment for atrial fibrillation. BMJ 1996; 312: 45-9.
24. Chen Y, Xu S, Bendahlou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003; 299: 251-4.